Skip to main content
BioPorto logo

BioPorto — Investor Relations & Filings

Ticker · BIOPOR ISIN · DK0011048619 LEI · 5299004SWFL5JAN4W830 CO Manufacturing
Open in API
Filings indexed 788 across all filing types
Latest filing 2022-09-08 Earnings Release
Country DK Denmark
Listing CO BIOPOR

About BioPorto

https://bioporto.com/

BioPorto is an in vitro diagnostics company specializing in actionable biomarkers to improve kidney health. The company's primary focus is the development and commercialization of diagnostic tests based on the Neutrophil Gelatinase-Associated Lipocalin (NGAL) biomarker for the early risk assessment and diagnosis of acute kidney injury (AKI). Its product portfolio includes The NGAL Test™ for clinical use and the FDA-cleared ProNephro AKI (NGAL) test for pediatric applications. These tools enable clinicians to detect kidney damage earlier than traditional methods, facilitating timely intervention. BioPorto also provides a range of NGAL ELISA kits and antibodies for preclinical and clinical research settings.

Recent filings

Filing Released Lang Actions
Earnings Release 2022
Earnings Release Classification · 100% confidence The document is titled "BioPorto Announces Interim Results for the First Six Months of 2022" and provides key financial highlights (revenue, Adjusted EBITDA) for the six months ending June 30, 2022, and the second quarter ending June 30, 2022. This content structure—a press release summarizing period-specific financial performance that is shorter than a full annual report—is characteristic of an Interim/Quarterly Report announcement. Although it contains highlights, the document itself is the announcement, not the full comprehensive report (which would likely be classified as IR). However, since it explicitly details the results for an interim period (First Six Months of 2022), the most appropriate classification among the provided options is Interim / Quarterly Report (IR), as it conveys the core financial data for that period, rather than just announcing the *release* of a separate document (RPA). The presence of a link to an attachment titled "Q2 Report 2022" confirms the subject matter is the interim results. H1 2022
2022-09-08 English
BioPorto Announces Interim Results for the First Six Months of 2022
Interim / Quarterly Report Classification · 100% confidence The document is an 'Interim Report' for BioPorto for the first half of 2022. It contains comprehensive financial statements, including consolidated financial highlights, balance sheets, income statements, and management's discussion and analysis (MDA) of the results. Although it is presented as an announcement, it provides the full substantive financial data and analysis required for an interim report, distinguishing it from a mere publication announcement (RPA). H1 2022
2022-09-08 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a press release dated June 28, 2022, announcing a clinical study milestone (achieving targeted enrollment) supporting an FDA De Novo submission for The NGAL Test. It discusses operational progress, future submission timelines, and references the 'Interim Report for First Quarter 2022' but does not contain the full financial statements or management discussion of that report. The content is a specific operational update intended for investors and the public, often distributed via news wires. This type of announcement, which is not a formal regulatory filing like a 10-K, a full Interim Report (IR), or a specific financial event (like DIV or CAP), fits best under the general category for regulatory/news announcements that don't fit elsewhere, which is Regulatory Filings (RNS). It is not an Earnings Release (ER) as it focuses on clinical progress, not financial results highlights.
2022-06-28 English
BioPorto Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S.
Regulatory Filings Classification · 95% confidence The document is a press release issued by BioPorto A/S regarding the achievement of a clinical study milestone for their NGAL Test, specifically related to FDA De Novo submission progress. It does not constitute a formal financial report, audit, or proxy statement. As it is a general corporate announcement regarding operational progress and regulatory milestones that does not fit into more specific categories like M&A or share issuance, it is classified as a general regulatory filing/announcement.
2022-06-28 English
Annual Report 2021
Annual Report Classification · 95% confidence The document is a comprehensive management review and financial report for BioPorto covering the fiscal year 2021. It includes detailed financial statements (income statement, balance sheet, cash flow statement), management discussion and analysis, corporate governance, risk management, and an independent auditor's report. The presence of full financial statements and detailed management commentary indicates this is a full annual report. The document length (15,000 characters) and content depth confirm it is not a brief announcement or a regulatory filing. Therefore, the document fits the definition of an Annual Report (10-K). FY 2021
2022-04-06 English
Report Publication Announcement 2022
Report Publication Announcement Classification · 100% confidence The document is titled "BioPorto Publishes 2021 Annual Report" and explicitly states that the company "today published its Annual Report for 2021." It includes financial highlights from 2021 and discusses the company's strategy and outlook, which are typical components of an Annual Report. However, the document itself is an announcement (Announcement no. 7) that directs the reader to the full report via links under the 'Attachments' section (e.g., 'Annual Report 2021'). According to Rule 2 (The 'MENU VS MEAL' Rule), if the document is an announcement stating a report has been published and provides links to the actual report, it should be classified as a Report Publication Announcement (RPA). Although the content is substantial, the primary function of this specific text is to announce the availability of the 2021 Annual Report, not to be the full, comprehensive 10-K filing itself. Therefore, RPA is the most accurate classification based on the document's structure as a press release announcing the report's release.
2022-04-06 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.